On average, physicians vote at a rate 5% lower than the general population. In a world where political decisions impact nearly every aspect of our lives, voting is crucial for creating a policy environment that allows rheumatology practices to thrive.
In Memoriam … Sheldon Mark Cooper, MD, MACR
Sheldon Mark Cooper, MD, MACR, professor of medicine, and a colleague and mentor throughout my career at the University of Vermont, Burlington, passed away June 6, after a long illness. Dr. Cooper was born in The Bronx, New York, in 1942, earning his medical degree from New York University School of Medicine in 1967. He…
Axial Spondyloarthritis: Research that Matters
Axial spondyloarthritis (axSpA), comprising ankylosing spondylitis (AS) and nonradiographic axial SpA, is the main form of chronic inflammatory arthritis affecting the axial skeleton. What research in axial spondyloarthrits to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future…
ACR-Led Coalition Working Toward Legislative Solutions for Underwater Biosimilars
The Underwater Biosimilars Coalition will meet with the Medicare Payment Advisory Commission to discuss concerns about inadequate reimbursement for certain biosimilars, which has limited beneficiary access to these lower-cost alternative therapies.
Resources for Practices to Fight Payer Downcoding of E/M Services
The American Medical Association and ACR Insurance Subcommittee offer support and guidance to help practices recognize and push back against downcoded payments for evaluation and management services.
Affiliate Society Council Active & Reenergized, Reports Chair Gwenesta B. Melton, MD
ASC Chair Gwenesta B. Melton, MD, shares the connections and activities that are helping the council develop stronger ties in and outside the ACR.
Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
B Cell-Depleting Therapy in SLE
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
An Expert’s Take on the Best Research in RA to Be Presented at ACR Convergence 2024
With thousands of research abstracts and posters being presented at ACR Convergence 2024, Nov. 14–19, at the Walter E. Washington Convention Center in Washington, D.C., figuring out which research is important today, which could prove important in the future, what has the potential to affect clinical care or prove the basis for future research is…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 812
- Next Page »